ALFA Finder
21:07 IST
NSE
Earnings Call
Piramal Pharma Investor Presentation: Key Takeaways
Q2FY27 revenue ₹2,617 Cr (+28% YoY), EBITDA margin 14.7% (+372 bps), PAT ₹5 Cr vs loss of ₹99 Cr. FY27 revenue growth outlook raised to 19-20%.
Piramal Pharma Ltd
- Share price
- ₹248.95
- Market cap
- ₹33,144 Cr
- Revenue (annual)
- ₹8,869 Cr
- Net profit (annual)
- ₹-325.9 Cr
- P/E (TTM)
- -158.7×Sector 43.8×
- Promoter holding
- 34.80%+0.00% QoQ
- FII holding
- 13.65%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
All
Other Announcement 7Business Update 7Financial Results 4Results Update 3Share Pledge 2Regulatory Approval 2Price Movement Clarification 2Merger & Restructuring 2Management Change 2Employee Stock Options 2Earnings Call 2Board Meeting Date 2Annual General Meeting 2Adverse Business Impact 2Legal & Regulatory 1Capital Structure Change 1
Time
2 announcements with these filters
20:54 IST
NSE
Earnings Call
Piramal Pharma Investor Presentation: Key Takeaways
Piramal Pharma started FY27 with 17% revenue growth and 72% EBITDA expansion. Momentum was driven by CDMO recovery and power brands.